Drug intelligence / Profile preview

GNU100-H

Development stage: Preclinical
Lead developer: Gnubiotics Sciences
Modality: Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

GNU100-H is a glycan-based nutritional candidate developed by Gnubiotics Sciences, utilizing their proprietary AMObiome platform. It is designed for human nutrition and microbiome support. The AMObiome platform focuses on complex glycans, which are structural mimics of human milk oligosaccharides (HMOs), designed to selectively nourish beneficial gut bacteria. While Gnubiotics has commercialized a similar product for pet health (GNU100), GNU100-H is specifically positioned for human applications to promote a healthy gut environment and support the microbiome.

Brand names: AMObiome
Other names: AMObiome

Beyond the preview

Go deeper on GNU100-H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNU100-H.

Explore the full profile